Eargo 8 OTC Hearing Aid Debuts
Eargo 8—Eargo's most advanced, virtually invisible over-the-counter hearing aid—features smart technology, extended battery life, and comprehensive support.
Eargo 8—Eargo's most advanced, virtually invisible over-the-counter hearing aid—features smart technology, extended battery life, and comprehensive support.
Patient Square’s equity ownership of Eargo resulted from the conversion of Patient Square’s senior secured convertible notes per its previously announced investment in June 2022 and following the recent closing of Eargo’s successful rights offering of common stock.
A recent article appearing on the “NBC News” website by Phil Galewitz with “Kaiser Health News,” discusses the expansion of over-the-counter hearing devices currently on the market for people with mild-to-moderate hearing loss, in the absence of FDA regulations governing the 2017 “Over-the-Counter Hearing Aid Law.”
With the rise of telecare and DIY/self-fit hearing devices (for at least milder hearing losses), hearing healthcare stakeholders will need to determine how and in what markets they do business.
Read MoreA new Google Alphabet project codenamed “Wolverine” aims to develop sensor technology to improve hearing while in a noisy environment, according to an article on “The Verge.”
Read MoreAlly’s alignment with Eargo builds upon the company’s legacy and expanding footprint in business-to-business-to-consumer lending.
Read MoreEargo, Inc (Nasdaq: EAR) a medical device company on a mission to improve the quality of life for...
Read MoreEargo reported that net revenue was $18.2 million for the third quarter of 2020, compared to $7.7 million in the third quarter of 2019. The company says the increase was driven by an increase in consumer adoption of the Eargo hearing aid system and a decrease in sales return accrual rate.
Read MoreEargo raised $141 million during its recent IPO, according to an article on the “Forbes” website, “sending shares up 87% on its first day of public trading.”
Read MoreEargo, Inc. (“Eargo”), a medical device company dedicated to improving the quality of life of people with hearing loss, announced the pricing of its initial public offering of 7,851,852 shares of its common stock at a public offering price of $18.00 per share.
Read MoreHearing aid companies report that patient usage of online hearing tests has increased by as much as 500% since the onset of the coronavirus pandemic in late March 2020.
Read MoreEargo announced the closing of a $71 million equity financing, led by new co-investors Gilde Healthcare and Longitude Capital, with existing investors New Enterprise Associates (NEA), the Charles and Helen Schwab Foundation, and Nan Fung Life Sciences, also participating in the round.
Read MoreEargo announced that they are doubling their commitment to healthcare professionals and their families by giving away “1 million in value of their virtually invisible hearing aids.” This offer is an expansion of the company’s previous commitment of $500,000 worth of value, as announced on March 30.
Read MoreTo help all with hearing needs, Eargo has set up a hearing hotline at 1-800-885-HEAR which will be available Monday through Friday from 9 am-5 pm ET. Also available at no cost are hearing health educational resources that can be found at eargo.com.
Read MoreAuthor Eddie Yoon, a founder of Eddie Would Grow, wrote that “Eargo’s team are trained to talk about hearing loss not as a medical problem, but rather as a relational problem,” and ask callers about the quality of conversations with friends and family.
Read MoreEargo, a medical device company “dedicated to improving the quality of life of people with hearing...
Read MoreUnless you’ve been locked in your soundbooth for the past three years, you’re probably well aware that a new class of over-the-counter (OTC) hearing aids will get the green light from the US Food and Drug Administration (FDA) sometime around August 2020, with the notice of proposed rulemaking (NPRM) slated for this November.
Read MoreUnless you’ve been locked in your soundbooth for the past three years, you’re probably well aware that a new class of over-the-counter (OTC) hearing aids will get the green light from the US Food and Drug Administration (FDA) sometime around August 2020, with the notice of proposed rulemaking (NPRM) slated for this November.
Read More